Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mandatory Metabolic Syndrome Check In Japan Provides Opportunities For Pharma Companies

This article was originally published in PharmAsia News

Executive Summary

Starting this April, Japanese health insurers will be required to provide annual health checks to beneficiaries 40-74 years old in an effort to reduce the number of metabolic syndrome patients. Pharmaceutical companies such as Novartis, Novo Nordisk and Pfizer have leveraged this new requirement to launch various public relations campaigns. Novartis Japan has sponsored a campaign to raise public awareness of hypertension. Novartis cites that among 350 million hypertension patients in Japan, only 7.8 million are receiving treatment. Danish company Novo Nordisk, the world's top insulin drug maker, has conducted a survey on lifestyle diseases among working Japanese ages 30 to 40, and found that on average 32 is the age for people to have the tendency of becoming overweight. And with an April launch of a smoking cessation drug, Pfizer has banned employee smoking inside the company as a measure to prevent smoking caused lifestyle diseases. (Click here for more-Japanese language

You may also be interested in...

Like Consumer Health Ad Claims About COVID-19, Customer Testimonials Are False And Misleading

Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading. 

Biopharma Deal Value, Volume Tumbled Substantially During First Half

A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.

Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug

Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts